235 related articles for article (PubMed ID: 19164467)
1. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition.
Hu X; Dietz JD; Xia C; Knight DR; Loging WT; Smith AH; Yuan H; Perry DA; Keiser J
Endocrinology; 2009 May; 150(5):2211-9. PubMed ID: 19164467
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels.
Clerc RG; Stauffer A; Weibel F; Hainaut E; Perez A; Hoflack JC; Bénardeau A; Pflieger P; Garriz JM; Funder JW; Capponi AM; Niesor EJ
J Hypertens; 2010 Aug; 28(8):1676-86. PubMed ID: 20498617
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility.
Kalgutkar AS; Frederick KS; Hatch HL; Ambler CM; Perry DA; Garigipati RS; Chang GC; Lefker BA; Clark RW; Morehouse LA; Francone O; Hu X
Xenobiotica; 2014 Jul; 44(7):591-605. PubMed ID: 24380613
[TBL] [Abstract][Full Text] [Related]
4. Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure.
Blasi E; Bamberger M; Knight D; Engwall M; Wolk R; Winter S; Betts A; John-Baptiste A; Keiser J
J Cardiovasc Pharmacol; 2009 Jun; 53(6):507-16. PubMed ID: 19455053
[TBL] [Abstract][Full Text] [Related]
5. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
Johns DG; Duffy J; Fisher T; Hubbard BK; Forrest MJ
Drugs; 2012 Mar; 72(4):491-507. PubMed ID: 22356288
[TBL] [Abstract][Full Text] [Related]
6. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone.
Forrest MJ; Bloomfield D; Briscoe RJ; Brown PN; Cumiskey AM; Ehrhart J; Hershey JC; Keller WJ; Ma X; McPherson HE; Messina E; Peterson LB; Sharif-Rodriguez W; Siegl PK; Sinclair PJ; Sparrow CP; Stevenson AS; Sun SY; Tsai C; Vargas H; Walker M; West SH; White V; Woltmann RF
Br J Pharmacol; 2008 Aug; 154(7):1465-73. PubMed ID: 18536749
[TBL] [Abstract][Full Text] [Related]
7. Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition.
Connelly MA; Parry TJ; Giardino EC; Huang Z; Cheung WM; Chen C; Cools F; Van der Linde H; Gallacher DJ; Kuo GH; Sarich TC; Demarest KT; Damiano BP
J Cardiovasc Pharmacol; 2010 May; 55(5):459-68. PubMed ID: 20051879
[TBL] [Abstract][Full Text] [Related]
8. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.
Vergeer M; Bots ML; van Leuven SI; Basart DC; Sijbrands EJ; Evans GW; Grobbee DE; Visseren FL; Stalenhoef AF; Stroes ES; Kastelein JJ
Circulation; 2008 Dec; 118(24):2515-22. PubMed ID: 19029469
[TBL] [Abstract][Full Text] [Related]
9. The failure of torcetrapib: what have we learned?
Joy TR; Hegele RA
Br J Pharmacol; 2008 Aug; 154(7):1379-81. PubMed ID: 18536741
[TBL] [Abstract][Full Text] [Related]
10. HDL metabolism and CETP inhibition.
Barkowski RS; Frishman WH
Cardiol Rev; 2008; 16(3):154-62. PubMed ID: 18414186
[TBL] [Abstract][Full Text] [Related]
11. Cholesteryl ester-transfer protein inhibitors stimulate aldosterone biosynthesis in adipocytes through Nox-dependent processes.
Rios FJ; Neves KB; Nguyen Dinh Cat A; Even S; Palacios R; Montezano AC; Touyz RM
J Pharmacol Exp Ther; 2015 Apr; 353(1):27-34. PubMed ID: 25617244
[TBL] [Abstract][Full Text] [Related]
12. Spotlight on HDL-raising therapies: insights from the torcetrapib trials.
Kontush A; Guérin M; Chapman MJ
Nat Clin Pract Cardiovasc Med; 2008 Jun; 5(6):329-36. PubMed ID: 18431367
[TBL] [Abstract][Full Text] [Related]
13. Update on CETP inhibition.
Davidson MH
J Clin Lipidol; 2010; 4(5):394-8. PubMed ID: 21122682
[TBL] [Abstract][Full Text] [Related]
14. Effects of torcetrapib in patients at high risk for coronary events.
Barter PJ; Caulfield M; Eriksson M; Grundy SM; Kastelein JJ; Komajda M; Lopez-Sendon J; Mosca L; Tardif JC; Waters DD; Shear CL; Revkin JH; Buhr KA; Fisher MR; Tall AR; Brewer B;
N Engl J Med; 2007 Nov; 357(21):2109-22. PubMed ID: 17984165
[TBL] [Abstract][Full Text] [Related]
15. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.
Barter P
Am J Cardiol; 2009 Nov; 104(10 Suppl):10E-5E. PubMed ID: 19895939
[TBL] [Abstract][Full Text] [Related]
16. The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors.
Vergeer M; Stroes ES
Am J Cardiol; 2009 Nov; 104(10 Suppl):32E-8E. PubMed ID: 19895942
[TBL] [Abstract][Full Text] [Related]
17. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure.
Cao G; Beyer TP; Zhang Y; Schmidt RJ; Chen YQ; Cockerham SL; Zimmerman KM; Karathanasis SK; Cannady EA; Fields T; Mantlo NB
J Lipid Res; 2011 Dec; 52(12):2169-2176. PubMed ID: 21957197
[TBL] [Abstract][Full Text] [Related]
18. Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib.
Williams SA; Murthy AC; DeLisle RK; Hyde C; Malarstig A; Ostroff R; Weiss SJ; Segal MR; Ganz P
Circulation; 2018 Mar; 137(10):999-1010. PubMed ID: 28974520
[TBL] [Abstract][Full Text] [Related]
19. Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
Shinkai H
Expert Opin Ther Pat; 2009 Sep; 19(9):1229-37. PubMed ID: 19663630
[TBL] [Abstract][Full Text] [Related]
20. Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms.
Sofat R; Hingorani AD; Smeeth L; Humphries SE; Talmud PJ; Cooper J; Shah T; Sandhu MS; Ricketts SL; Boekholdt SM; Wareham N; Khaw KT; Kumari M; Kivimaki M; Marmot M; Asselbergs FW; van der Harst P; Dullaart RP; Navis G; van Veldhuisen DJ; Van Gilst WH; Thompson JF; McCaskie P; Palmer LJ; Arca M; Quagliarini F; Gaudio C; Cambien F; Nicaud V; Poirer O; Gudnason V; Isaacs A; Witteman JC; van Duijn CM; Pencina M; Vasan RS; D'Agostino RB; Ordovas J; Li TY; Kakko S; Kauma H; Savolainen MJ; Kesäniemi YA; Sandhofer A; Paulweber B; Sorli JV; Goto A; Yokoyama S; Okumura K; Horne BD; Packard C; Freeman D; Ford I; Sattar N; McCormack V; Lawlor DA; Ebrahim S; Smith GD; Kastelein JJ; Deanfield J; Casas JP
Circulation; 2010 Jan; 121(1):52-62. PubMed ID: 20026784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]